Commercialization of Cell Therapy-Related Products in Taiwan: A Case Study of Biotech Company T

• Main Authors: Ting-Yu Huang, 黃廷宇
• Other Authors: 黃恆獎
• Format: Others
• Language: zh-TW
• Published: 2019
• Online Access: http://ndltd.ncl.edu.tw/handle/zdgm67

碩士 === 國立臺灣大學 === 事業經營碩士在職學位學程 === 107 === In the 21st century, the whole world is now facing the problem of overpopulation, aging society, disease prevention, caner treatment and the rising of the awareness of public health. The biotechnology is considered to be another star industry, and each government invests progressively the growth of start-up biotech companies. In addition to the traditional drug development in biotech industry, the cell therapy in regeneration medicine is regarded as new type of treatment. Scientists assume this new kind of treatment would be able to cure those diseases that cannot be cured by traditional treatment. Cell therapy in Taiwan has been accumulated some certain levels of development. Although the relevant regulations are started lately and ambiguously, the government progresses step by step to the international standards. However, there is no benchmark standard of cell therapy company in Taiwan, and also few relevant industrial research data could be reach. Therefore, we select T company, a start-up cell therapy company in Taiwan, as our research subject and try to identify those key successful factors, and analyze how to manage those limited resources efficiently to a start-up cell therapy company via literature collection and internal interviews. We propose corresponding strategies and expect this research become the pioneer study in cell therapy related industries in Taiwan.